Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
Overview
Paper Summary
This small study investigated whether an intranasal chlorpheniramine spray, typically used for allergies, could help prevent or mitigate post-acute sequelae of SARS-CoV-2 infection (PASC), also known as "long COVID." The study involved a small number of participants from two previous clinical trials and found that those who received the spray reported significantly fewer long-COVID symptoms. However, it is important to note the small sample size and the lack of standardized treatment protocols limit the reliability of the findings.
Explain Like I'm Five
A nose spray used for allergies might help prevent long-COVID. A small study of people recovering from COVID showed fewer long-term problems if they used the spray.
Possible Conflicts of Interest
This research was funded by Dr. Ferrer Biopharma, which could potentially introduce a conflict of interest. No other conflicts were identified.
Identified Limitations
Rating Explanation
This study presents some interesting preliminary findings, but the small sample size and other methodological limitations warrant a cautious interpretation and a rating of 3. Larger, more rigorous studies are needed to confirm these results.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →